Phesgo (pertuzumab/trastuzumab/hyaluronidase-zzxf) / Roche, Halozyme 
Welcome,         Profile    Billing    Logout  

22 Trials

   Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Phesgo (pertuzumab/trastuzumab/hyaluronidase-zzxf) / Roche
2020-004241-36: STUDY OF A SUBCUTANEOUS FIXED-DOSE COMBINATION OF PERTUZUMAB AND TRASTUZUMAB FOR THE TREATMENT OF PATIENTS WITH HER2-POSITIVE EARLY BREAST CANCER ESTUDIO CLINICO DE LA COMBINACION DE UNA DOSIS FIJA SUBCUTÁNEA DE PERTUZUMAB Y TRASTUZUMAB PARA EL TRATAMIENTO DE PACIENTES CON CÁNCER DE MAMA PRECOZ HER2 POSITIVO

Not yet recruiting
4
33
Europe
Fixed dose combination of pertuzumab and trastuzumab, Pertuzumab, Trastuzumab, Fixed dose combination of pertuzumab and trastuzumab RO7198574, RO7198574, RO4368451, RO0452317, Solution for injection, Concentrate for solution for infusion, Powder for concentrate and solution for solution for infusion, Perjeta, Herceptin
Roche Farma S.A, Roche Farma S.A
EARLY BREAST CANCER Cáncer de mama temprano, Breast cancer is a type of cancer that forms in the cells of the breast El cáncer de mama es un tipo de cáncer que se forma en las células de las mamas, Diseases [C] - Cancer [C04]
 
 
2023-000156-38: Health economic analysis of pertuzumab and trastuzumab for metastatic breast cancer

Not yet recruiting
4
90
Europe
pertuzumab, trastuzumab, pertuzumab, trastuzumab, Solution for injection, Solution for infusion, Powder for concentrate for solution for infusion, Phesgo 600/600, Perjeta, Herzuma
Semmelweis University, Department of Internal Medicine and Oncology, Semmelweis University, Roche Magyarország Kft.
HER-2 positive advanced breast cancer, locally unresectable or metastatic breast cancer, Metastatic, advanced breast cancer, Diseases [C] - Cancer [C04]
 
 
FeDeriCa, NCT03493854 / 2017-004897-32: A Study to Evaluate the Pharmacokinetics, Efficacy, and Safety of Subcutaneous Administration of the Fixed-Dose Combination of Pertuzumab and Trastuzumab in Combination With Chemotherapy in Participants With HER2-Positive Early Breast Cancer

Checkmark Data from FEDERICA trial in combination with Perjeta for HER2+ breast cancer
Nov 2019 - Nov 2019: Data from FEDERICA trial in combination with Perjeta for HER2+ breast cancer
Completed
3
500
Europe, Canada, Japan, US, RoW
Cyclophosphamide, Doxorubicin, Docetaxel, Paclitaxel, Pertuzumab IV, Perjeta, RO4368451, FDC of Pertuzumab and Trastuzumab SC, Pertuzumab, Trastuzumab, and Hyaluronidase-zzxf, RO7198574, RG6264, Trastuzumab IV, Herceptin, RO0452317, Trastuzumab SC, Surgery, Post-operative Radiotherapy, Hormone Therapy
Hoffmann-La Roche
Early Breast Cancer
07/19
06/23
NCT04024462: A Two-Arm Study to Evaluate the Pharmacokinetics, Efficacy, and Safety of Subcutaneous Administration of the Fixed-Dose Combination of Pertuzumab and Trastuzumab in Combination With Chemotherapy in Chinese Participants With HER2-Positive Early Breast Cancer

Active, not recruiting
3
200
RoW
Pertuzumab IV, Perjeta, RO4368451, Trastuzumab IV, Herceptin, RO0452317, Pertuzumab and Trastuzumab FDC SC, Pertuzumab, Trastuzumab, and Hyaluronidase-zzxf, PHESGO™, PH FDC SC, RG6264, RO7198574, Doxorubicin, Cyclophosphamide, Docetaxel, Surgery, Post-Operative Radiotherapy, Hormone Therapy
Hoffmann-La Roche
HER2-positive Early Breast Cancer
12/21
11/25
ProHer, NCT05415215 / 2021-002346-33: A Study to Evaluate Patient Preference for Home Administration of Fixed-Dose Combination of Pertuzumab and Trastuzumab for Subcutaneous Administration in Participants With Early or Locally Advanced/Inflammatory HER2-Positive Breast Cancer

Active, not recruiting
3
347
Europe, Canada, RoW
Fixed Dose Combination of Pertuzumab and Trastuzumab for Subcutaneous Use (PH FDC SC), PHESGO®, Pertuzumab, Trastuzumab, and Hyaluronidase-zzxf, Pertuzumab, Trastuzumab, and rHuPH20, RO7198574, RG6264, Pertuzumab IV, Perjeta®, RO4368451, Trastuzumab IV, Herceptin®, RO0452317, Trastuzumab Emtansine, Kadcyla®, ado-trastuzumab emtansine, T-DM1, RO5304020, Investigator's Choice of Chemotherapy, Surgery, Radiotherapy
Hoffmann-La Roche, F. Hoffmann-La Roche Ltd
Early Breast Cancer, Locally Advanced Breast Cancer, Inflammatory Breast Cancer
03/25
12/25
HER2CLIMB-05, NCT05132582 / 2021-002491-39: A Study of Tucatinib or Placebo With Trastuzumab and Pertuzumab for Metastatic HER2+ Breast Cancer

Recruiting
3
650
Europe, Canada, Japan, US, RoW
Tucatinib, TUKYSA, ONT-380, ARRY-380, Trastuzumab, Herceptin, Herceptin Hylecta, Pertuzumab, Perjeta, Combination product: Trastuzumab + Pertuzumab, Phesgo, Placebo
Seagen Inc., Merck Sharp & Dohme LLC
HER2 Positive Breast Cancer
10/24
06/27
heredERA, NCT05296798: A Study to Evaluate the Efficacy and Safety of Giredestrant in Combination With Phesgo (Pertuzumab, Trastuzumab, and Hyaluronidase-zzxf) Versus Phesgo in Participants With Locally Advanced or Metastatic Breast Cancer ( Breast Cancer)

Recruiting
3
812
Europe, US, RoW
Phesgo, Pertuzumab, Trastuzumab, and Hyaluronidase-zzxf, Pertuzumab, Trastuzumab, and rHuPH20, Fixed-Dose Combination of Pertuzumab and Trastuzumab for Subcutaneous Use (PH FDC SC), RO7198574, RG6264, Giredestrant, GDC-9545, RO7197597, RG6171, Docetaxel, Paclitaxel, LHRH Agonist, Optional Endocrine Therapy of Investigator's Choice
Hoffmann-La Roche
Locally Advanced or Metastatic Breast Cancer
08/26
09/32
INAVO122, NCT05894239: A Study to Evaluate the Efficacy and Safety of Inavolisib in Combination With Phesgo Versus Placebo in Combination With Phesgo in Participants With PIK3CA-Mutated HER2-Positive Locally Advanced or Metastatic Breast Cancer

Recruiting
3
230
Europe, Canada, US, RoW
Inavolisib, Phesgo, Placebo, Taxane-based Chemotherapy, non-investigational medicinal product (NIMP), Optional Endocrine Therapy of Investigator's Choice, NIMP
Hoffmann-La Roche
Metastatic Breast Cancer
10/28
10/28
2021-002323-38: Neoadjuvant endocrine therapy in combination with trastuzumab, pertuzumab with or without inavolisib Neoadjuvante endokrine Therapie in Kombination mit Trastuzumab, Pertuzumab mit oder ohne Inavolisib

Not yet recruiting
2
170
Europe
inavolisib (GDC-0077), Phesgo, RO7113755, RO7198574, Film-coated tablet, Solution for injection in vial, Phesgo
German Breast Group, F. Hoffmann-La Roche Ltd
Patients with early breast cancer Patienten mit primärem Brustkrebs, Patients with early breast cancer Patienten mit primärem Brustkrebs, Diseases [C] - Cancer [C04]
 
 
2022-003865-39: Treatment of HER2+ early breast cancer with either trastuzumab-deruxtecan or standard-of-care treatment (chemotherapy + antibodies) Behandlung von frühem, HER2-positiven Brustkrebs mit Trastuzumab-Deruxtecan im Vergleich zu Standardtherapie (Chemotherapie + Antikörper)

Not yet recruiting
2
402
Europe
Trastuzumab-Deruxtecan (T-DXd), Paclitaxel, Docetaxel, Carboplatin, Trastuzumab, Phesgo, Pertuzumab, DS-8201a, Powder for concentrate for solution for infusion, Concentrate for solution for injection/infusion, Solution for injection, Enhertu
Westdeutsche Studiengruppe GmbH, AstraZeneca
HER2+ early breast cancer HER2+ früher Brustkrebs, Breast Cancer Brustkrebs, Diseases [C] - Cancer [C04]
 
 
MyTACTIC, NCT04632992: A Study Evaluating Targeted Therapies in Participants Who Have Advanced Solid Tumors With Genomic Alterations or Protein Expression Patterns Predictive of Response

Completed
2
252
US
Entrectinib, Rozlytrek™, RG6268, RO7102122, Inavolisib, GDC-0077, RG6114, RO7113755, Alectinib, Alecensa®, RG7853, RO5424802, Ipatasertib, GDC-0068, RG7440, RO5532961, Atezolizumab, Tecentriq®, RG7446, RO5541267, Trastuzumab Emtansine, Kadcyla®, RG3502, RO5304020, Pertuzumab, Trastuzumab, and Hyaluronidase-zzxf, PHESGO™, PH FDC SC, Fixed dose combination of trastuzumab and pertuzumab administered subcutaneously, RG6264, RO7198574, Tucatinib, Tukysa™, Investigator's Choice of Chemotherapy, Paclitaxel, Tiragolumab, RG6058, RO7092284, MTIG7192A, Pralsetinib, GAVRETO™, RG6396, RO7499790
Genentech, Inc.
Advanced Unresectable or Metastatic Solid Malignancy
12/23
02/24
DEMETHER, NCT06172127: PHESGO Maintenance After T-DXd Short Induction for HER2+ Unresectable Locally Recurrent or Metastatic Breast Cancer

Not yet recruiting
2
165
NA
Trastuzumab deruxtecan, T-DXd, Phesgo 1,200 MG / 600 MG / 30,000 UNT Per 15 ML Injection, PHESGO, Pertuzumab-Trastuzumab FDC SC, Phesgo 600 MG / 600 MG / 20,000 UNT in 10 mL Injection
MedSIR, Hoffmann-La Roche
HER2-positive Breast Cancer
11/26
05/29
TAPUR, NCT02693535: Testing the Use of Food and Drug Administration (FDA) Approved Drugs That Target a Specific Abnormality in a Tumor Gene in People With Advanced Stage Cancer

Recruiting
2
3791
US
Palbociclib, Ibrance, Sunitinib, Sutent, Temsirolimus, Torisel, Trastuzumab and Pertuzumab, Herceptin and Perjeta, Vemurafenib and Cobimetinib, Zelboraf and Cotellic, Regorafenib, Stivarga, Olaparib, Lynparza, Pembrolizumab, Keytruda, Nivolumab and Ipilimumab, Opdivo and Yervoy, Abemaciclib, Verzenio, Talazoparib, Talzenna, Atezolizumab and PHESGO, Tecentriq and PHESGO, Atezolizumab and Talazoparib, Tecentriq and Talzenna, Entrectinib, Rozlytrek, Larotrectinib, Vitrakvi, Tucatinib plus Trastuzumab Subcutaneous (SC), Tukysa and Herceptin Hylecta, Futibatinib, Lytgobi
American Society of Clinical Oncology, AstraZeneca, Bayer, Bristol-Myers Squibb, Eli Lilly and Company, Genentech, Inc., Merck Sharp & Dohme LLC, Pfizer, Boehringer Ingelheim, Seagen Inc., Taiho Oncology, Inc.
Lymphoma, Non-Hodgkin, Multiple Myeloma, Advanced Solid Tumors
12/24
12/25
PHERGAIN-2, NCT04733118 / 2020-003205-66: Chemotherapy-Free pCR-Guided Strategy With Trastuzumab-pertuzumab and T-DM1 in HER2-positive Early Breast Cancer

Active, not recruiting
2
393
Europe
Trastuzumab and Pertuzumab (FDC SC) and T-DM1, Trastuzumab emtansine, Phesgo, Kadcyla
MedSIR, Hoffmann-La Roche
Early Breast Cancer
09/25
03/28
CHERRY-PICK, NCT06068985: Classifying for HER2 Dependence to De-Escalate Neoadjuvant Chemotherapy in Patients With HER2+ Early Breast Cancer Undergoing HER2 Double-Blockade

Not yet recruiting
2
63
RoW
PHESGO
Latin American Cooperative Oncology Group, Roche Pharma AG, Oncoclínicas
Breast Cancer, HER2-positive Breast Cancer
10/26
10/31
ADEPT, NCT04569747: A Single Arm Phase II Study of ADjuvant Endocrine Therapy, Pertuzumab, and Trastuzumab for Patients With Anatomic Stage I Hormone Receptor-positive, HER2-positive Breast Cancer

Recruiting
2
375
US
Pertuzumab+TRASTUZUMAB, PHESGO, ADJUVANT ENDOCRINE THERAPY, Letrozole, Anastrozole, Exemestane, Tamoxifen, Leuprolide, or other LHRH agonist (per investigator discretion)
Dana-Farber Cancer Institute, Genentech, Inc.
HER2-positive Breast Cancer, Invasive Carcinoma of the Breast, Breast Cancer, Node Negative Breast Cancer, Micrometastasis Breast Cancer, Hormone Receptor Positive Breast Cancer
09/26
09/30
GeparPiPPa, NCT05306041: Neoadjuvant Endocrine Therapy +/- the PI3K Inhibitor Inavolisib in HER2+, HR+, PIK3CA Mutant Early Breast Cancer

Recruiting
2
170
Europe
Inavolisib, PHESGO, Endocrine therapy
German Breast Group, Roche Pharma AG
HER2-positive Breast Cancer
10/26
01/27
Decrescendo, NCT04675827: De-escalation Adjuvant Chemo in HER2+/ER-/Node-neg Early BC Patients Who Achieved pCR After Neoadjuvant Chemo & Dual HER2 Blockade

Suspended
2
1065
Europe, RoW
Pertuzumab and tratuzumab fixed dose combination, Adjuvant pertuzumab + trastuzumab FDC SC for 14 cycles, Fixed-dose combination of Perjeta and Herceptin for subcutaneous injection for 14 cycles, Trastuzumab emtansine, Adjuvant T-DM1
Jules Bordet Institute, Breast International Group, Hoffmann-La Roche, International Drug Development Institute, Institut Curie
HER2-positive Breast Cancer, ER-Negative Breast Cancer, PR-Negative Breast Cancer, Node-negative Breast Cancer
06/27
03/29
MORPHEUS BC, NCT04802759: A Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Participants With Breast Cancer

Recruiting
1/2
510
Europe, US, RoW
Giredestrant, GDC-9545, RO7197597, RG6171, Abemaciclib, Verzenio™, Ipatasertib, GDC-0068, RO5532961, RG7440, Inavolisib, GDC-0077, RO7113755, RG6114, Ribociclib, Kisqali®, Everolimus, Afinitor®, Samuraciclib, ICEC0942, CT7001, PH FDC SC, Pertuzumab, Trastuzumab, and Hyaluronidase-zzxf, PHESGO™, RO7198574, RG6264, Palbociclib, Ibrance®, Atezolizumab, Tecentriq®, RO5541267, RG7446
Hoffmann-La Roche
Inoperable, Locally Advanced or Metastatic, ER-positive Breast Cancer
04/26
10/26
NCT05275010: A Study in Healthy Male Subjects to Investigate the Comparability of Pharmacokinetics of the Fixed-Dose Combination of Pertuzumab and Trastuzumab Administered Subcutaneously Using a Handheld Syringe or Using the On-Body Delivery System

Completed
1
151
RoW
Fixed-Dose Combination of Pertuzumab and Trastuzumab SC (PH FDC SC), Pertuzumab, Trastuzumab, and Hyaluronidase-zzxf, PHESGO®, RO7198574, RG6264, Handheld Syringe with Hypodermic Needle, On-Body Delivery System
Hoffmann-La Roche
Healthy Male Subjects
05/23
10/23
NCT05593094: A Phase 1 Trial of ZN-A-1041 Enteric Capsules or Combination in Patients With HER2-Positive Advanced Solid Tumors

Recruiting
1
210
US
ZN-A-1041 50mg BID, ZN-A-1041 Enteric Capsules, ZN-A-1041 100mg BID, ZN-A-1041 200mg BID, ZN-A-1041 400mg BID, ZN-A-1041 600mg BID, ZN-A-1041 800mg BID, ZN-A-1041 1000mg BID, ZN-A-1041 + T-DM1 3.6 mg/kg iv. for Phase1b, ZN-A-1041 + T-Dxd 5.4 mg/kg iv. for Phase1b, ZN-A-1041 + PHESGO / Herceptin plus Perjeta injection for Phase1b, ZN-A-1041 + T-DM1 3.6 mg/kg iv. for Phase1c, ZN-A-1041 + T-Dxd 5.4 mg/kg iv. for Phase1c, ZN-A-1041 + PHESGO / Herceptin plus Perjeta injection for Phase1c
Suzhou Zanrong Pharma Limited
Advanced Solid Tumors, HER2-positive Breast Cancer
10/23
10/24
ACT, NCT05238831: SMMART Adaptive Clinical Treatment () Trial

Withdrawn
1
25
NA
Alectinib, AF-802, AF802, Alecensa, ALK Inhibitor RO5424802, CH5424802, RG7853, RO5424802, Alpelisib, BYL719, Phosphoinositide 3-kinase Inhibitor BYL719, Piqray, VIJOICE, Anastrozole, Anastrazole, Arimidex, ICI D1033, ICI-D1033, ZD-1033, Atezolizumab, MPDL 3280A, MPDL 328OA, MPDL-3280A, MPDL3280A, MPDL328OA, RG7446, RO5541267, Tecentriq, Bevacizumab, ABP 215, Anti-VEGF, Anti-VEGF Humanized Monoclonal Antibody, Anti-VEGF Monoclonal Antibody SIBP04, Anti-VEGF rhuMAb, Avastin, Bevacizumab awwb, Bevacizumab Biosimilar ABP 215, Bevacizumab Biosimilar BEVZ92, Bevacizumab Biosimilar BI 695502, Bevacizumab Biosimilar CBT 124, Bevacizumab Biosimilar CT-P16, Bevacizumab Biosimilar FKB238, Bevacizumab Biosimilar GB-222, Bevacizumab Biosimilar HD204, Bevacizumab Biosimilar HLX04, Bevacizumab Biosimilar IBI305, Bevacizumab Biosimilar LY01008, Bevacizumab Biosimilar MIL60, Bevacizumab Biosimilar Mvasi, Bevacizumab Biosimilar MYL-1402O, Bevacizumab Biosimilar QL 1101, Bevacizumab Biosimilar QL1101, Bevacizumab Biosimilar RPH-001, Bevacizumab Biosimilar SCT501, Bevacizumab Biosimilar Zirabev, Bevacizumab-awwb, Bevacizumab-bvzr, BP102, BP102 Biosimilar, HD204, Immunoglobulin G1 (Human-Mouse Monoclonal rhuMab-VEGF Gamma-Chain Anti-Human Vascular Endothelial Growth Factor), Disulfide With Human-Mouse Monoclonal rhuMab-VEGF Light Chain, Dimer, Mvasi, MYL-1402O, QL1101, Recombinant Humanized Anti-VEGF Monoclonal Antibody, rhuMab-VEGF, SCT501, SIBP 04, SIBP-04, SIBP04, Zirabev, Biopsy, BIOPSY_TYPE, Bx, Biospecimen Collection, Biological Sample Collection, Biospecimen Collected, Specimen Collection, Capecitabine, Ro 09-1978/000, Xeloda, Carboplatin, Blastocarb, Carboplat, Carboplatin Hexal, Carboplatino, Carboplatinum, Carbosin, Carbosol, Carbotec, CBDCA, Displata, Ercar, JM-8, Nealorin, Novoplatinum, Paraplatin, Paraplatin AQ, Paraplatine, Platinwas, Ribocarbo, Cobimetinib, Cotellic, GDC-0973, MEK Inhibitor GDC-0973, XL518, Entrectinib, Rozlytrek, RXDX 101, RXDX-101, RXDX101, Eribulin, ER-086526, Fulvestrant, Faslodex, Faslodex(ICI 182,780), ICI 182,780, ICI 182780, ZD9238, Hyaluronidase-zzxf/Pertuzumab/Trastuzumab, Pertuzumab, Trastuzumab, and Hyaluronidase-zzxf, Pertuzumab/Trastuzumab/Hyaluronidase-zzxf, Phesgo, Irinotecan, Letrozole, CGS 20267, Femara, Nab-paclitaxel, ABI 007, ABI-007, Abraxane, Albumin-bound Paclitaxel, Albumin-Stabilized Nanoparticle Paclitaxel, Nanoparticle Albumin-bound Paclitaxel, Nanoparticle Paclitaxel, Paclitaxel Albumin, paclitaxel albumin-stabilized nanoparticle formulation, Protein-bound Paclitaxel, Niraparib, MK-4827, MK4827, Olaparib, AZD 2281, AZD-2281, AZD2281, KU-0059436, Lynparza, PARP Inhibitor AZD2281, Paclitaxel, Anzatax, Asotax, Bristaxol, Praxel, Taxol, Taxol Konzentrat, Palbociclib, 6-Acetyl-8-cyclopentyl-5-methyl-2-((5-(piperazin-1-yl)pyridin-2-yl)amino)-8h-pyrido(2,3-d)pyrimidin-7-one, Ibrance, PD 0332991, PD 332991, PD 991, PD-0332991, Pertuzumab, 2C4, 2C4 Antibody, EG1206A, HLX11, HS627, MoAb 2C4, Monoclonal Antibody 2C4, Omnitarg, Perjeta, Pertuzumab Biosimilar EG1206A, Pertuzumab Biosimilar HLX11, Pertuzumab Biosimilar HS627, rhuMAb2C4, RO4368451, Quality-of-Life Assessment, Quality of Life Assessment, Trastuzumab, ABP 980, ALT02, Anti-c-ERB-2, Anti-c-erbB2 Monoclonal Antibody, Anti-ERB-2, Anti-erbB-2, Anti-erbB2 Monoclonal Antibody, Anti-HER2/c-erbB2 Monoclonal Antibody, Anti-p185-HER2, c-erb-2 Monoclonal Antibody, HER2 Monoclonal Antibody, Herceptin, Herceptin Biosimilar PF-05280014, Herceptin Trastuzumab Biosimilar PF-05280014, Herzuma, Kanjinti, MoAb HER2, Monoclonal Antibody c-erb-2, Monoclonal Antibody HER2, Ogivri, Ontruzant, PF-05280014, QL 1701, QL-1701, QL1701, rhuMAb HER2, RO0452317, SB3, Trastuzumab Biosimilar ABP 980, Trastuzumab Biosimilar ALT02, trastuzumab biosimilar EG12014, Trastuzumab Biosimilar HLX02, Trastuzumab Biosimilar PF-05280014, Trastuzumab Biosimilar QL1701, Trastuzumab Biosimilar SB3, Trastuzumab Biosimilar SIBP-01, Trastuzumab-anns, Trastuzumab-dkst, Trastuzumab-dttb, Trastuzumab-pkrb, Trastuzumab-qyyp, Trazimera, Trastuzumab Emtansine, Ado Trastuzumab Emtansine, ADO-Trastuzumab Emtansine, Kadcyla, PRO132365, RO5304020, T-DM1, Trastuzumab-DM1, Trastuzumab-MCC-DM1, Trastuzumab-MCC-DM1 Antibody-Drug Conjugate, Trastuzumab-MCC-DM1 Immunoconjugate, Vemurafenib, BRAF (V600E) kinase inhibitor RO5185426, BRAF(V600E) Kinase Inhibitor RO5185426, PLX-4032, PLX4032, RG 7204, RG7204, RO 5185426, Zelboraf, Vinorelbine, Dihydroxydeoxynorvinkaleukoblastine, Vismodegib, Erivedge, GDC-0449, Hedgehog Antagonist GDC-0449
OHSU Knight Cancer Institute, Genentech, Inc., Oregon Health and Science University
Advanced Breast Carcinoma, Advanced Malignant Solid Neoplasm, Advanced Ovarian Carcinoma, Advanced Pancreatic Carcinoma, Advanced Prostate Carcinoma, Advanced Sarcoma, Anatomic Stage III Breast Cancer AJCC v8, Anatomic Stage IV Breast Cancer AJCC v8, Recurrent Adult Soft Tissue Sarcoma, Recurrent Breast Carcinoma, Recurrent Ovarian Carcinoma, Recurrent Prostate Carcinoma, Stage II Pancreatic Cancer AJCC v8, Stage III Ovarian Cancer AJCC v8, Stage III Pancreatic Cancer AJCC v8, Stage IV Ovarian Cancer AJCC v8, Stage IV Pancreatic Cancer AJCC v8
05/26
05/26

Download Options